Announcement of exclusive license agreement for development, manufacturing and sale of glycerol phenylbutyrate in Japan
Announcement of exclusive license agreement for development, manufacturing and sale of glycerol phenylbutyrate in Japan
Home > News & Events > Announcement of exclusive license agreement for development, manufacturing and sale of glycerol phenylbutyrate in Japan
Announcement of exclusive license agreement for development, manufacturing and sale of glycerol phenylbutyrate in Japan
OrphanPacific, Inc. and Immedica Pharma AB announced that on May 2, 2022, both companies signed an exclusive license agreement for the following rights in Japan:
Development, manufacturing and sale of glycerol phenylbutyrate (the brand name in the United States and Europe: Ravicti®) for the treatment of Urea Cycle Disorders (UCD)
Orphan Pacific was established by CMIC Holdings, a leading contract research organization (CRO) in Japan, and Medipal Holdings, which has more than 300 bases nationwide and develops distribution businesses for pharmaceuticals and medical devices. Two companies with abundant achievements in the medical field have teamed up to cover everything from drug development to sales. We have realized the manufacture and sale of orphan drugs through low-cost operations. To learn more about Orphan Pacific, Inc., please visit: https://www.orphanpacific.com/
Inquiries about our services
Click below if you are interested in outsourcing your operations to us.